ISSN: 2167-7700

Chemotherapy: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Gary L. Johanning
Gary L. Johanning Gary L. Johanning
Associate Professor
University of Texas
Tel. 512-332-5211
Fax 512-332-7375

Gary L. Johanning, MS, PhD, is an Associate Professor of Comparative Medicine at the Michale E. Keeling Center for Comparative Medicine and Research with the University of Texas MD Anderson Cancer Center at Bastrop TX.  He received his B.S., M.S. and PhD in Biochemistry from the University of Missouri at Columbia and completed a postdoctoral fellowship in the Biochemistry Department at Case Western Reserve University.  He is an Editorial Board Member of Cancer Management and Research and The Open Lung Cancer Journal, and is Associate Editor of Nutrition and Dietary Supplements. He has been awarded grants from the National Institutes of Health, the Department of Defense and several foundations.  He is a member of the Executive Committee of The Nutritional Sciences Council. His primary research interests include micronutrients and their effect on chemotherapy efficacy, nutrition and cancer, endogenous retroviruses, and cancer prevention and immunotherapy. 

Research Interest

A major goal of the research in Dr. Johanning’s laboratory is to determine the role of the vitamin folic acid (folate) in carcinogenesis, cancer prevention, and immune response. An important aspect of this research is evaluating the influence of folic acid on the development of resistance to cisplatin and other chemotherapeutic agents. Cancer cells can become resistant to the cytotoxic action of chemotherapeutic agents either at the outset (intrinsic resistance) or after the agents are administered for a period of time (acquired resistance). Resistance to cisplatin and other agents is an important problem in cancer therapy, and the mechanism by which resistance develops is not clear. Dr. Johanning has obtained data indicating that folic acid can prevent the development of both intrinsic and acquired resistance to cisplatin in lung and ovarian cancer cell lines.


Global Speakers in the subject

Global Experts in the subject


Stapled Peptides as Anti-Apoptotic Drugs
Gary L. Johanning
Editorial: Chemotherapy 2012, 1: e109
DOI: 10.4172/2167-7700.100e109

Chemotherapy: Open Access - FOLIC ACID

Associate Professor
University of Texas

Download PPT PPT Views: 177 Updated on: 2014-11-04 For Recent Update: Click here
Download PDF   PDF Views: 177  Updated on: 2014-11-04 For Recent Update: Click here
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version